o Onyx Pharmaceuticals Inc., of Emeryville, Calif., and Bayer HealthCare Pharmaceuticals Inc., of Wayne, N.J., said that they have begun enrolling patients in an international Phase III trial to evaluate Nexavar (sorafenib) tablets for advanced or metastatic thyroid cancer. The Phase III trial will enroll about 400 thyroid cancer patients who have received no prior systemic therapy. The primary endpoint of the study is progression-free survival, and secondary endpoints will include overall survival, time to progression and response rate. The safety and tolerability of the two treatment groups also will be compared.
o Shire plc, of Basingstoke, UK, said data showed that …
Комментариев нет:
Отправить комментарий